Certara Products - Simcyp Archives | Page 5 of 21

Blog

Simcyp PBPK Simulatorをお客様の医薬品開発プログラムに統合する10のメリット

Per US FDA’s recent paper on the topic, Physiologically based Pharmacokinetic (PBPK) modeling & simulation…

Certara2021年6月22日

On-Demand Webinar

PBPK modeling approaches to assess risks associated with bioequivalence in drug development

In this webinar, Dr. Ioannis Loisios-Konstantinidis from Novartis, Switzerland discussed: Opportunities and challenges in conducting…

Jim Gallagher2021年5月19日

Publication

Opening a debate on open‐source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate

As model‐informed drug development becomes an integral part of modern approaches to the discovery of…

Jim Gallagher2021年5月13日

On-Demand Webinar

A Best Practice Framework for Applying PBPK Modeling to Pediatric Drug Development

Pediatric PBPK models have broad application in the drug development process and are being used…

Jim Gallagher2021年4月20日

White Paper

Overcome Research Hurdles: Expert Guidance for Complex Generic Drug Development

Do expensive bioequivalence studies stall your generic drug approval? Learn how you can streamline complex…

Certara2021年4月15日

On-Demand Webinar

Predicting the Effect of the Dulaglutide-Mediated Gastric Emptying Delay on Drug Exposure

The European Medicines Agency (EMA) recently approved dulaglutide (Trulicity®) at higher doses (3 mg and…

Jim Gallagher2021年4月1日

Blog

Simcyp Simulator Impacts 80+ Novel Drugs

250 Label claims using PBPK without the need for additional clinical studies “Clinical Studies and…

Certara2021年3月17日

Publication

Physiologically- based pharmacokinetic modeling to support bioequivalence and approval of generic products: A case for diclofenac sodium topical gel, 1%

Jim Gallagher2021年3月16日

On-Demand Webinar

IQ WG Evaluation of PBPK Models for Organ-Impaired Populations

• The predictive performance of physiologically based pharmacokinetic(s) (PBPK) models for PK in renal impairment…

Jim Gallagher2021年3月10日

White Paper

Simcyp PBPK を用いた小児用医薬品開発の促進

Jim Gallagher2021年3月4日

Powered by Translations.com GlobalLink Web Software

Certara Products – Simcyp

Simcyp PBPK Simulatorをお客様の医薬品開発プログラムに統合する10のメリット

PBPK modeling approaches to assess risks associated with bioequivalence in drug development

Opening a debate on open‐source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate

A Best Practice Framework for Applying PBPK Modeling to Pediatric Drug Development

Overcome Research Hurdles: Expert Guidance for Complex Generic Drug Development

Predicting the Effect of the Dulaglutide-Mediated Gastric Emptying Delay on Drug Exposure

Simcyp Simulator Impacts 80+ Novel Drugs

Physiologically- based pharmacokinetic modeling to support bioequivalence and approval of generic products: A case for diclofenac sodium topical gel, 1%

IQ WG Evaluation of PBPK Models for Organ-Impaired Populations

Simcyp PBPK を用いた小児用医薬品開発の促進

メルマガ登録

クイックアクセス

ソリューション

お問合せ